History & Evolution

The ESPEN Reference Laboratory has a long-standing legacy rooted in the Onchocerciasis Control Programme (OCP), established in 1991 in Ouagadougou, Burkina Faso. Initially created to support entomological and parasitological surveillance for onchocerciasis control in West Africa, the laboratory became a regional center of expertise for vector identification and molecular diagnostics.

The ESPEN Laboratory’s 80-seat training and conference room used for regional workshops, meetings, and capacity-building sessions

Following the transition from OCP to the African Programme for Onchocerciasis Control (APOC) and later to the Expanded Special Project for the Elimination of Neglected Tropical Diseases (ESPEN), the laboratory’s mandate expanded beyond onchocerciasis to include lymphatic filariasis and other preventive chemotherapy NTDs. Over time, it has evolved into a WHO-supported regional reference facility providing standardized diagnostic services, quality assurance, and technical training for Member States.

Laboratory bench equipped for molecular and serological assays, including PCR and ELISA for onchocerciasis and lymphatic filariasis surveillance

Recent investments by ESPEN and partners, including The END Fund and African Society for Laboratory Medicine (ASML), have modernized its infrastructure, upgraded equipment, and strengthened quality systems. The laboratory now stands as a cornerstone of the regional NTD elimination strategy, contributing to evidence generation, innovation, and capacity building across Africa.

History of the ESPEN Reference Laboratory

Major Milestones

1991 – Origins under OCP:
Established within the Onchocerciasis Control Programme (OCP), the laboratory began its mission supporting entomological and parasitological surveillance across West Africa.
2016–2022 – Integration and Expansion:
Incorporated into the Expanded Special Project for the Elimination of NTDs (ESPEN), the laboratory broadened its portfolio to include new diagnostic assays, training programmes, and regional technical support.
2023–2024 – Modernization and Growth:
Expanded capacity for molecular and serological testing, scaled up regional training, and launched the Diagnostic Hub to improve access to essential reagents and supplies.
2025 – Quality Systems Strengthened:
Completion of a comprehensive technical audit, infrastructure and warehouse upgrades, and reinforcement of the External Quality Assessment (EQA) scheme.
2025–2030 – Towards Regional Designation:
Implementation of a strategic roadmap positioning the facility as a WHO-designated Regional Reference Laboratory for PC-NTDs, supporting countries in verification and elimination processes.